The federal government’s reclassification of medical marijuana products as Schedule III drugs doesn’t federally legalize marijuana, but it might extend tax breaks to some cannabis businesses. The federal government has changed its view of marijuana’s dependence and abuse risks, causing some confusion about what that means for Americans.

The federal government is reclassifying medical marijuana, categorizing it as a drug with potential medical benefits and less potential for harm. While this doesn’t legalize marijuana nationally, it does open the door for further research into its effects.

By Puyaan Singh and Christy Santhosh April 30 (Reuters) - Companies developing cannabis-based medicines say U.S. moves to loosen restrictions on the drug could unlock private funding and the public markets,

Over the last three decades, 40 states have legalized the sale and use of medical marijuana in one form or another. Last week, the federal government followed suit, and the policy change could have significant repercussions on employers.

The DEA announced the new requirements for medical marijuana dispensaries seeking federal compliance, including application details and costs.

The U.S. administration is expected to reclassify marijuana as a less dangerous drug as soon as Wednesday, Axios reported, citing an official

President Donald Trump called on Congress Thursday to take action to repeal and reform the impending hemp ban that would wipe out nearly all hemp-derived CBD products on the market. “I am calling on Congress to update the Law to ensure that Americans can continue to access the full-spectrum CBD products they have come to